CN102802631A - 与长效注射用帕潘立酮酯相关的给药方案 - Google Patents

与长效注射用帕潘立酮酯相关的给药方案 Download PDF

Info

Publication number
CN102802631A
CN102802631A CN2010800504164A CN201080050416A CN102802631A CN 102802631 A CN102802631 A CN 102802631A CN 2010800504164 A CN2010800504164 A CN 2010800504164A CN 201080050416 A CN201080050416 A CN 201080050416A CN 102802631 A CN102802631 A CN 102802631A
Authority
CN
China
Prior art keywords
paliperidone
dose
patient
day
cetylate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800504164A
Other languages
English (en)
Chinese (zh)
Inventor
P·H·卢伊恩-布里斯克
C·加斯曼-迈尔
S·戈帕尔
D·W·霍夫
B·M·M·雷默里
M·N·萨姆塔尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43302985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102802631(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN102802631A publication Critical patent/CN102802631A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800504164A 2009-10-30 2010-10-29 与长效注射用帕潘立酮酯相关的给药方案 Pending CN102802631A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25669609P 2009-10-30 2009-10-30
US61/256696 2009-10-30
PCT/US2010/054807 WO2011053829A1 (en) 2009-10-30 2010-10-29 Dosing regimen associated with long-acting injectable paliperidone esters

Publications (1)

Publication Number Publication Date
CN102802631A true CN102802631A (zh) 2012-11-28

Family

ID=43302985

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800504164A Pending CN102802631A (zh) 2009-10-30 2010-10-29 与长效注射用帕潘立酮酯相关的给药方案

Country Status (12)

Country Link
US (2) US20110105536A1 (enExample)
EP (1) EP2493473A1 (enExample)
JP (2) JP2013509435A (enExample)
KR (1) KR20120116401A (enExample)
CN (1) CN102802631A (enExample)
AU (2) AU2010313290A1 (enExample)
BR (1) BR112012010195A2 (enExample)
CA (1) CA2742393A1 (enExample)
CL (1) CL2012001110A1 (enExample)
MX (1) MX2012005083A (enExample)
NZ (1) NZ599558A (enExample)
WO (1) WO2011053829A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI877363B (zh) * 2020-11-30 2025-03-21 比利時商健生藥品公司 與延釋帕利哌酮可注射配製物相關之投藥方案（三）

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR102163196B1 (ko) 2007-12-19 2020-10-12 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
WO2011114213A1 (en) 2010-03-15 2011-09-22 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
EP3156056B1 (en) 2011-03-18 2023-12-06 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
CA2867121C (en) 2012-03-19 2021-05-25 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
AU2013235523B9 (en) 2012-03-19 2018-01-04 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising glycerol esters
AU2013235526B2 (en) * 2012-03-19 2017-11-30 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
ES2792149T3 (es) 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
AU2015231278B2 (en) 2014-03-20 2020-01-23 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
KR102755145B1 (ko) * 2015-04-07 2025-01-14 잔센파마슈티카엔.브이. 장기간 작용형 주사용 팔리페리돈 에스테르에 대한 누락된 용량에 대한 투여 계획
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CA3155912A1 (en) 2019-09-25 2021-04-01 Janssen Pharmaceuticals, Inc. Interconnection of drug administration systems
US20220062557A1 (en) * 2020-09-02 2022-03-03 Janssen Pharmaceutica Nv Pre-filled syringe with optimized stopper placement
US11324751B1 (en) * 2020-11-30 2022-05-10 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
FI4025189T3 (fi) * 2020-11-30 2024-07-02 Janssen Pharmaceutica Nv Viivästetysti vapauttavaan injektoitavaan paliperidoniin liittyviä annostusohjelmia
MX2023010925A (es) * 2021-03-17 2023-09-27 Medincell S A Formulacion inyectable de accion prolongada que comprende risperidona y polimeros biodegradables.
CN118119394A (zh) 2021-08-20 2024-05-31 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
WO2009080651A1 (en) * 2007-12-19 2009-07-02 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
KR100338776B1 (ko) 2000-07-11 2002-05-31 윤종용 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造
DE202007018474U1 (de) * 2006-08-14 2008-08-07 Teva Pharmaceutical Industries Ltd. Kirstallformen von 9-Hydroxy-Risperidon (Paliperidon)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070197591A1 (en) * 2005-12-12 2007-08-23 Sandra Boom Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function
WO2009080651A1 (en) * 2007-12-19 2009-07-02 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI877363B (zh) * 2020-11-30 2025-03-21 比利時商健生藥品公司 與延釋帕利哌酮可注射配製物相關之投藥方案（三）

Also Published As

Publication number Publication date
JP2016102123A (ja) 2016-06-02
EP2493473A1 (en) 2012-09-05
AU2010313290A1 (en) 2012-05-17
MX2012005083A (es) 2012-09-28
NZ599558A (en) 2014-09-26
JP2013509435A (ja) 2013-03-14
US20130331402A1 (en) 2013-12-12
WO2011053829A1 (en) 2011-05-05
CL2012001110A1 (es) 2012-10-19
KR20120116401A (ko) 2012-10-22
US20110105536A1 (en) 2011-05-05
CA2742393A1 (en) 2011-05-05
AU2015243103A1 (en) 2015-11-05
BR112012010195A2 (pt) 2016-04-26

Similar Documents

Publication Publication Date Title
CN102802631A (zh) 与长效注射用帕潘立酮酯相关的给药方案
JP5825786B2 (ja) 長時間作用型注入可能パリペリドンエステルに関連する投薬計画
JP7422277B2 (ja) 長時間作用型注射可能パリペリドンエステルの抜かした投与量のための投与レジメン
US20230085549A1 (en) Dosing Regimens Associated With Extended Release Paliperidone Injectable Formulations
KR20230116837A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
KR20230116836A (ko) 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
HK40110149A (en) Dosing regimen for missed doses for long-acting injectable paliperidone esters

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121128